The main goal of this investigator-initiated study is to evaluate the effectiveness and
efficacy of Teriflunomide in a population of Relapsing Remitting Multiple Sclerosis (RRMS)
patients treated in regular practice, over a period of at least two years, in the regular
setting of a Multiple Sclerosis Clinic.